Get the Stockscreener App
10.63
1.14%
0.12
Olema Pharmaceuticals Inc stock is traded at $10.63, with a volume of 1.16M.
It is up +1.14% in the last 24 hours and down -10.30% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$10.51
Open:
$10.44
24h Volume:
1.16M
Relative Volume:
0.82
Market Cap:
$930.10M
Revenue:
-
Net Income/Loss:
$-185.15M
P/E Ratio:
-5.2486
EPS:
-2.0253
Net Cash Flow:
$-148.72M
1W Performance:
-11.78%
1M Performance:
-10.30%
6M Performance:
-52.94%
1Y Performance:
+102.09%
1-Day Range:
$10.29
$10.75
1-Week Range:
$9.70
$12.20
52-Week Range:
$5.29
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
10.63 | 913.48M | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-19-26 | Resumed | Jefferies | Buy |
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
OLMA Maintained by JP Morgan -- Price Target Lowered to $46.00 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals, Inc. Announces Appointment of Jason O?Byrne to Chief Financial Officer, Effective August 11, 2026 - marketscreener.com
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46 - Moomoo
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
HC Wainwright Brokers Decrease Earnings Estimates for OLMA - MarketBeat
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - The Manila Times
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech - Stock Titan
Olema Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harmon Cyrus - Moomoo
Olema stock falls 12.9% as Q2 loss widens to $63.2M on R&D spend - scanx.trade
OLMA Maintains Rating by Citigroup -- Price Target Lowered to $59 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup - MarketBeat
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 - benzinga.com
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings - MarketBeat
Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39.9, Implies 234% Upside - TradingView
OLMA Maintains Buy Rating -- Price Target Lowered to $36.00 by H - GuruFocus
H.C. Wainwright lowers Olema Pharmaceuticals price target to $36 By Investing.com - Investing.com Canada
Olema Pharmaceuticals (OLMA) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Olema Pharmaceuticals Q2 Loss Widens - marketscreener.com
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss - marketscreener.com
Olema Oncology (OLMA) Advances Phase 3 Trial Enrollment Amid Mixed Market Signals - GuruFocus
Olema Pharmaceuticals falls 6% on second quarter EPS miss By Investing.com - Investing.com Canada
Olema Pharmaceuticals falls 6% on second quarter EPS miss - Investing.com
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Olema Pharmaceuticals (OLMA) widens net loss but ends Q2 2026 with $461M in cash - Stock Titan
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results - Yahoo Finance
Olema Pharmaceuticals earnings up next ahead of key trial data - Investing.com
Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
FMR LLC, Abigail Johnson disclose 13.8% Olema Pharmaceuticals (OLMA) ownership - Stock Titan
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Seven New Hires Get Olema Stock Options at $11.28 a Share - Stock Titan
Olema grants stock options for 254,540 shares to seven new employees under inducement plan - Bitget
Olema Pharmaceuticals (OLMA) Expected to Release Quarterly Earnings on Monday - MarketBeat
Defilade Capital Management L.P. Acquires 269,902 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Janus Henderson Group PLC Boosts Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells 12,500 Shares of Stock - MarketBeat
Form 4 Olema Pharmaceuticals Inc For: 27 July By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals director Cyrus Harmon sells $291k in stock By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals director Cyrus Harmon sells $291k in stock - Investing.com
Olema Pharmaceuticals Inc (OLMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Olema Pharmaceuticals Inc (OLMA) Cash Flow - TradingKey
OLMA|Olema Pharmaceuticals Inc|Price:12.020|Chg%:+0.320 - TradingKey
Olema Pharmaceuticals Inc (OLMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Olema Pharmaceuticals Inc (OLMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Olema Pharmaceuticals (OLMA) Holds Near Support Amid Modest DeclinePCR Extreme - po-news-eg.net
OLMA|Olema Pharmaceuticals Inc|Price:11.905|Chg%:-0.145 - TradingKey
Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):